Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>

The liver fluke <i>Fasciola hepatica</i> is an economically important global pathogen of humans and their livestock. To facilitate host invasion and migration, <i>F. hepatica</i> secretes an abundance of cathepsin peptidases but prevents excessive damage to both parasite and...

Full description

Bibliographic Details
Main Authors: Krystyna Cwiklinski, Orla Drysdale, Jesús López Corrales, Yolanda Corripio-Miyar, Carolina De Marco Verissimo, Heather Jewhurst, David Smith, Richard Lalor, Tom N. McNeilly, John P. Dalton
Format: Article
Language:English
Published: MDPI AG 2022-01-01
Series:Vaccines
Subjects:
Online Access:https://www.mdpi.com/2076-393X/10/2/155
_version_ 1827652352818020352
author Krystyna Cwiklinski
Orla Drysdale
Jesús López Corrales
Yolanda Corripio-Miyar
Carolina De Marco Verissimo
Heather Jewhurst
David Smith
Richard Lalor
Tom N. McNeilly
John P. Dalton
author_facet Krystyna Cwiklinski
Orla Drysdale
Jesús López Corrales
Yolanda Corripio-Miyar
Carolina De Marco Verissimo
Heather Jewhurst
David Smith
Richard Lalor
Tom N. McNeilly
John P. Dalton
author_sort Krystyna Cwiklinski
collection DOAJ
description The liver fluke <i>Fasciola hepatica</i> is an economically important global pathogen of humans and their livestock. To facilitate host invasion and migration, <i>F. hepatica</i> secretes an abundance of cathepsin peptidases but prevents excessive damage to both parasite and host tissues by co-secreting regulatory peptidase inhibitors, cystatins/stefins and Kunitz-type inhibitors. Here, we report a vaccine strategy aimed at disrupting the parasite’s protease/anti-protease balance by targeting these key inhibitors. Our vaccine cocktail containing three recombinant stefins (rFhStf-1, rFhStf-2, rFhStf-3) and a Kunitz-type inhibitor (rFhKT1) formulated in adjuvant Montanide 61VG was assessed in two independent sheep trials. While fluke burden was not reduced in either trial, in Trial 1 the vaccinated animals showed significantly greater weight gain (<i>p</i> < 0.05) relative to the non-vaccinated control group. In both trials we observed a significant reduction in egg viability (36–42%). Multivariate regression analyses showed vaccination and increased levels of IgG2 antibodies specific for the <i>F. hepatica</i> peptidase inhibitors were positive indicators for increased weight gain and levels of haemoglobin within the normal range at 16 weeks post-infection (wpi; <i>p</i> < 0.05). These studies point to the potential of targeting peptidase inhibitors as vaccine cocktails for fasciolosis control in sheep.
first_indexed 2024-03-09T20:54:17Z
format Article
id doaj.art-3371f8ffa1b94ba784a90fbdeafd0833
institution Directory Open Access Journal
issn 2076-393X
language English
last_indexed 2024-03-09T20:54:17Z
publishDate 2022-01-01
publisher MDPI AG
record_format Article
series Vaccines
spelling doaj.art-3371f8ffa1b94ba784a90fbdeafd08332023-11-23T22:24:25ZengMDPI AGVaccines2076-393X2022-01-0110215510.3390/vaccines10020155Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>Krystyna Cwiklinski0Orla Drysdale1Jesús López Corrales2Yolanda Corripio-Miyar3Carolina De Marco Verissimo4Heather Jewhurst5David Smith6Richard Lalor7Tom N. McNeilly8John P. Dalton9Molecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, IrelandSchool of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UKMolecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, IrelandMoredun Research Institute, Pentland Science Park, Penicuik, Midlothian EH26 0PZ, UKMolecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, IrelandMolecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, IrelandSchool of Biological Sciences, Medical Biology Centre, Queen’s University Belfast, Belfast BT9 5DL, UKMolecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, IrelandMoredun Research Institute, Pentland Science Park, Penicuik, Midlothian EH26 0PZ, UKMolecular Parasitology Laboratory, Centre for One Health, Ryan Institute, National University of Ireland Galway, H91 DK59 Galway, IrelandThe liver fluke <i>Fasciola hepatica</i> is an economically important global pathogen of humans and their livestock. To facilitate host invasion and migration, <i>F. hepatica</i> secretes an abundance of cathepsin peptidases but prevents excessive damage to both parasite and host tissues by co-secreting regulatory peptidase inhibitors, cystatins/stefins and Kunitz-type inhibitors. Here, we report a vaccine strategy aimed at disrupting the parasite’s protease/anti-protease balance by targeting these key inhibitors. Our vaccine cocktail containing three recombinant stefins (rFhStf-1, rFhStf-2, rFhStf-3) and a Kunitz-type inhibitor (rFhKT1) formulated in adjuvant Montanide 61VG was assessed in two independent sheep trials. While fluke burden was not reduced in either trial, in Trial 1 the vaccinated animals showed significantly greater weight gain (<i>p</i> < 0.05) relative to the non-vaccinated control group. In both trials we observed a significant reduction in egg viability (36–42%). Multivariate regression analyses showed vaccination and increased levels of IgG2 antibodies specific for the <i>F. hepatica</i> peptidase inhibitors were positive indicators for increased weight gain and levels of haemoglobin within the normal range at 16 weeks post-infection (wpi; <i>p</i> < 0.05). These studies point to the potential of targeting peptidase inhibitors as vaccine cocktails for fasciolosis control in sheep.https://www.mdpi.com/2076-393X/10/2/155<i>Fasciola hepatica</i>sheepvaccinesprotease-anti-protease balancestefinKunitz-type inhibitor
spellingShingle Krystyna Cwiklinski
Orla Drysdale
Jesús López Corrales
Yolanda Corripio-Miyar
Carolina De Marco Verissimo
Heather Jewhurst
David Smith
Richard Lalor
Tom N. McNeilly
John P. Dalton
Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>
Vaccines
<i>Fasciola hepatica</i>
sheep
vaccines
protease-anti-protease balance
stefin
Kunitz-type inhibitor
title Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>
title_full Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>
title_fullStr Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>
title_full_unstemmed Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>
title_short Targeting Secreted Protease/Anti-Protease Balance as a Vaccine Strategy against the Helminth <i>Fasciola hepatica</i>
title_sort targeting secreted protease anti protease balance as a vaccine strategy against the helminth i fasciola hepatica i
topic <i>Fasciola hepatica</i>
sheep
vaccines
protease-anti-protease balance
stefin
Kunitz-type inhibitor
url https://www.mdpi.com/2076-393X/10/2/155
work_keys_str_mv AT krystynacwiklinski targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT orladrysdale targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT jesuslopezcorrales targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT yolandacorripiomiyar targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT carolinademarcoverissimo targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT heatherjewhurst targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT davidsmith targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT richardlalor targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT tomnmcneilly targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai
AT johnpdalton targetingsecretedproteaseantiproteasebalanceasavaccinestrategyagainstthehelminthifasciolahepaticai